A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
DRUG: Acalabrutinib in combination with BR|DRUG: Acalabrutinib in combination with VR
Number of Participants with Treatment Emergent Adverse Events (AEs) as assessed by CTCAE v4.03, Number of participants who had experienced at least one treatment emergent AE, From first dose of study drug to within 30 days of last dose of study drug
This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when administered concomitantly with venetoclax and rituximab in subjects with treatment naive mantle cell lymphoma (Part 2).